Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 1.31 and has seen 0.66 million shares traded in the recent trading session. The INZY stock price is -472.48% off its 52-week high price of $6.24 and 33.94% above the 52-week low of $0.72.
The consensus among analysts is that Inozyme Pharma Inc (INZY) is Buy stock at the moment, with a recommendation rating of 1.12. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.4.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Sporting -0.46% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the INZY stock price touched $1.09 or saw a rise of 19.56%. Year-to-date, Inozyme Pharma Inc shares have moved -60.83%, while the 5-day performance has seen it change -18.42%. Over the past 30 days, the shares of Inozyme Pharma Inc (NASDAQ:INZY) have changed 11.96%.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 92.21% from the levels at last check today.. The projected low price target is $14.0 while the price target rests at a high of $16.0. In that case, then, we find that the latest price level in today’s session is -1367.89% off the targeted high while a plunge would see the stock gain -1184.4% from the levels at last check today..
Inozyme Pharma Inc (INZY) estimates and forecasts
The company’s shares have lost -73.01% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.98% over the past 5 years. Earnings growth for 2025 is a modest 14.97% while over the next 5 years, the company’s earnings are expected to increase by 14.09%.
INZY Dividends
Inozyme Pharma Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
The top two institutional holders are ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares worth more than $25.55 million. As of 2024-06-30, ADAGE CAPITAL PARTNERS GP, L.L.C. held 9.2484% of shares outstanding.
The other major institutional holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with the holding of over 4.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $20.05 million and represent 7.2563% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.44% shares in the company for having 2.22 shares of worth $2.52 million while later fund manager owns 1.56 shares of worth $1.77 million as of Dec 31, 2024 , which makes it owner of about 2.41% of company’s outstanding stock.
